TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01699412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol
Description: Rinse with a solution of clobetasol 0.05% associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Rinse with a solution of dexamethasone 0.1 mg/mL associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
Study: NCT01788150

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Stenting

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary Stenting
Study: NCT00387348

Intervention type: DRUG
Group type: OTHER
Intervention: escitalopram oxalate
Description: escitalopram oxalate 10 mg once daily for 4 weeks
Study: NCT02399644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Participants are going to perform a training programme including aerobic exercise as well as endurance and strength training for the neck, shoulders, low back, core and leg muscles. The training is group-based and supervised by a physiotherapist two times a week, one hour a time for eight weeks. Home exercises twice a week are also a part of the intervention. It is possible to individually adjust movements and intensity to the participants' capacity if needed.
Study: NCT02487953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: 21 mg/24 h for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: 21 mg/24 h for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS
Description: As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ENDS
Description: As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo patch
Description: 21 mg size for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg size for 2 weeks, and 7 mg size for 2 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo ENDS
Description: As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
Study: NCT00547963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief counseling
Description: baseline assessment + two 40 minute sessions of brief counseling
Study: NCT03150381

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Only
Description: 24- month weight loss program (year 1: weekly in person meetings for 6 months, followed by 2 meetings per month for 3 months, then monthly for 3 months; year 2: monthly phone calls)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Plus
Description: Participants will attend in-person weekly sessions (about 1.5 hours each) for 6 months and then twice a month for 3 months and monthly for 3 months. Sessions focus on behavioral techniques supporting healthy diet (including calorie restriction for weight loss) and achieving recommended amounts of physical activity per week. During 1-year weight loss maintenance, participants receive monthly motivational phone calls.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants receive quarterly newsletters containing generic cancer prevention messages and participate in community-wide cancer awareness educational sessions.
Study: NCT01035502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacytarabine plus idarubicin
Description: Elacytarabine 1000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.~Idarubicin will be administered IV at a fixed dose of 12 mg/ m2/d IV on d 1-3 q3w.~It is intended that patients receive remission-induction treatment either as two combination courses, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d or one combination course, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d followed by one course elacytarabine 2000 mg/m2/d single therapy.
Study: NCT00710983

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral polio vaccine
Study: NCT01697085

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sea buckthorn oil
Study: NCT02571777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol/fluticasone
Study: NCT01697085

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Study: NCT00394576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based nutrition module along with usual care
Description: usual care plus Internet-based nutrition module

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: usual care
Study: NCT03415503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medox® Anthocyanin capsules
Description: Subjects were orally administered Medox® capsules daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medox® Anthocyanin capsules
Description: Subjects were orally administered Medox® capsules daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medox® Anthocyanin capsules
Description: Subjects were orally administered Medox® capsules daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medox® Anthocyanin capsules
Description: Subjects were orally administered Medox® capsules daily for 12 weeks.
Study: NCT00387348

Intervention type: DRUG
Group type: OTHER
Intervention: escitalopram oxalate
Description: escitalopram oxalate 10 mg once daily for 4 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: one placebo pill identical in appearance to the escitalpram pill once daily

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: one placebo pill identical in appearance to the escitalpram pill once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one placebo pill identical in appearance to the escitalpram pill once daily
Study: NCT03214926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moving Through Glass intervention
Study: NCT01932931

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol (50ug)
Description: The aim of the study was to investigate the effect of high dose vitamin D3 supplementation on the muscoloskeletal system among patients treated with antidepressants due to a diagnosis of major depressive disorder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cholecalciferol (50ug)
Description: The aim of the study was to investigate the effect of high dose vitamin D3 supplementation on the muscoloskeletal system among patients treated with antidepressants due to a diagnosis of major depressive disorder
Study: NCT02786108

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: left gastric artery embolization

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: healthy diet and exercise
Study: NCT04779632

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Experimental: Fish Oil
Description: Participants are provided with fish oil capsules and asked to take 4 capsules of 1000 mg twice a day (in total 5.2 mg/day of long-chain n-3 fatty acids hereof 2400 mg of eicosapentaenoic acid and 1600 mg of docosahexaenoic acid) for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Experimental: Fish Oil
Description: Participants are provided with fish oil capsules and asked to take 4 capsules of 1000 mg twice a day (in total 5.2 mg/day of long-chain n-3 fatty acids hereof 2400 mg of eicosapentaenoic acid and 1600 mg of docosahexaenoic acid) for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Comparator: Safflower Oil
Description: Participants are provided with fish oil capsules and asked to take 4 capsules of 500 mg twice a day (containing \~ 3000 mg of linoleic acid) for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Comparator: Safflower Oil
Description: Participants are provided with fish oil capsules and asked to take 4 capsules of 500 mg twice a day (containing \~ 3000 mg of linoleic acid) for 4 weeks.
Study: NCT05622357

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short course radiation therapy followed by 6 cycles of CAPOX then surgery
Description: Short course RT 5 x5 Gy followed by 6 cycles CAPOX then surgery
Study: NCT04677998

Intervention type: PROCEDURE
Intervention: Personalized surveillance and intervention protocol
Description: This study uses one arm. Participants will undergo endoscopic surveillance with intervals between 3-6 months and 5 years, depending on severity of polyposis and performed endoscopic interventions.
Study: NCT01297283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LECG first
Description: Measurement of the pacing threshold with the support of a leadless ECG

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Programmer ECG first
Description: Pacing threshold measurements are done with the support of the programmer ECG
Study: NCT02468206

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon-occluded retrograde transvenous obliteration
Description: Balloon-occluded retrograde transvenous obliteration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic cyanoacrylate injection
Description: Endoscopic cyanoacrylate injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-butyl-2-cyanoacrylate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lauromacrogol
Study: NCT01726712

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Description: Provide emotional support. Provide practical support. Support friend/family by helping him find information or help for those with HIV in the community
Study: NCT03310437

Intervention type: PROCEDURE
Intervention: Primary PCI
Description: Primary percutaneous coronary intervention in acute myocardial infarction patients
Study: NCT01233700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Standard motivational interviewing techniques will be applied to assist subjects to consider and work to resolve any remaining concerns, doubts, or ambivalence about their decision about donating an organ to someone else.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Lifestyles Education
Description: Educational information will be presented to subjects in didactic form on lifestyles issues of relevance to living donors.
Study: NCT01925612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.2 mg/kg by IV infusion every 3 weeks for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg by IV infusion every 3 weeks for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg by IV infusion every 3 weeks for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg by IV infusion every 3 weeks for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: 1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: 1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: 1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
Study: NCT00948688

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Once per day, 5 days a week for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Intravenously over 24 hours, 7 days per week during each week of radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Taken orally. Dose will depend upon time of enrollment and how well previous participants tolerated the drug
Study: NCT03714607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erbium Yttrium Aluminum Garnet (Er:YAG) laser
Description: 5 Er:YAG laser therapies vaginally administered at monthly intervals
Study: NCT01152307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD/Booklet: Coping with Symptoms of Depression
Description: DVD and booklet that provides information about treatment choices for depression symptoms
Study: NCT00524121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Oral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative Study

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation Treatment
Study: NCT01840943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAELYX
Description: CAELYX 50 mg per square meter will be administered intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing for PK evaluation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan HCl
Description: Topotecan 1.25 mg per square meter per day will be administered, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.
Study: NCT00983034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lansoprazole, amoxicillin, clarithromycin
Description: lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lansoprazole, amoxicillin, clarithromycin
Description: lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lansoprazole, amoxicillin, clarithromycin
Description: lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days
Study: NCT02481193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Description: Different doses of cisatracurium pretreatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Description: Different doses of cisatracurium pretreatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Description: Different doses of cisatracurium pretreatment
Study: NCT01458678

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volume of colloid infusion
Description: Colloid infusion is primarily given as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volume of colloid infusion
Description: Colloid infusion is given primarily as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
Study: NCT02126995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG01CI extended-release tablet
Description: Metadoxine, MG01CI extended-release tablet taken for 6 weeks treatment. Starting with a dose of 700 mg for 2 weeks followed by a 2 weeks of 1400 mg and then 2 weeks of 700 mg or 1400 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MG01CI extended-release tablet
Description: Metadoxine, MG01CI extended-release tablet taken for 6 weeks treatment. Starting with a dose of 700 mg for 2 weeks followed by a 2 weeks of 1400 mg and then 2 weeks of 700 mg or 1400 mg.
Study: NCT02155790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Peregrine System Infusion Catheter
Description: The ASI catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
Study: NCT01773811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Writing: Trauma-Assigned
Description: Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the assigned group will be given instructions and weekly reminders to continue to think about their most traumatic event.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Narrative Writing: Trauma-Spontaneous
Description: Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the spontaneous group will be given no further instructions.
Study: NCT04603456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacteol fort
Description: Lacteol fort is a drug containing lactobacilli

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standardized Timothy Grass Pollen
Description: SLIT includes 2 phases build up and maintenance phases. (Jubilant HollisterStier LLC 14110 Collections Drive, Chicago USA) .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacteol fort and Standardized Timothy Grass Pollen
Description: Lacteol fort is a drug containing lactobacilli and the Standardized Timothy Grass Pollen includes 2 phases build up and maintenance phases.
Study: NCT03628820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dog Therapy
Description: 5 minutes spent with therapy dog during shift

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coloring
Description: 5 minutes spend coloring mandalas during shift
Study: NCT03500354

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrient drink
Description: High calorie drink with therapeutic supplements
Study: NCT00018031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: Weekly injections for 48 weeks of a dose of 1.5mcg/Kg per week subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Weight based Ribavirin dosing 1-1.2grams/day in divided (twice daily) doses for a total duration of 48 weeks.
Study: NCT01964833

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Periodontal treatment
Description: Periodontal treatment will consist of oral hygiene instructions, with the monitored orientation of brushing technique and recommendation of the daily use of dental floss. Calculus deposits will also be removed using ultrasound equipment with the appropriate tips for periodontics as well as scaling and planing with dental instruments, as recommended by the AAP (2001). Treatment will be carried out in two to four one-hour sessions.~Patient will receive sham PDT.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal treatment and PDT
Description: Patients will receive periodontal treatment as previously described and PDT. PDT will be administered at the end of the periodontal treatment session at sites with pocket depths equal to or greater than 4 mm. A diode laser will be used at the 660 nm wavelength, P= 100 mW, 9 J/point, D = 22 J/cm2 (per point). The photosensitizer (BlueMet 0.005 % DMC)will be deposited at the fundus of the periodontal pocket using a syringe. The laser will be applied to the mucosa over the oral epithelium that lines the periodontal pocket using an optical fiber.
Study: NCT00390065

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitric Oxide
Description: Early low dose (5ppm) NO inhalation Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Early low dose (5ppm) NO inhalation Placebo
Study: NCT02330237

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: natural gels
Description: whole fruits and vegetables
Study: NCT03100318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981
Description: Oral daily dosing for 14 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzbromarone
Description: Oral daily dosing for 14 weeks
Study: NCT04144777

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Solarplast
Description: Subjects will take one capsule of Solarplast (100mg) daily for 45 days.
Study: NCT04563767

Intervention type: PROCEDURE
Intervention: Infinitome
Description: Added sequence of rs-fMRI.
Study: NCT00696033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: Diazépam drug (0,3 mg/kg) on a single oral intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Lorazépam drug (0,038 mg/kg) on a single oral intake

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: lorazépam placebo or Diazépam placebo
Study: NCT01925612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Study: NCT00938262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan, Ketoconazole, Rifampicin
Description: Fimasartan (1 day)~Ketoconazole (3 days) Ketoconazole + Fimasartan (1 day)~Rifampicin (9 days) Rifampicin + Fimasartan (1 day)
Study: NCT01001351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT-201
Description: Applied topically during surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Applied topically during surgery
Study: NCT00548197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: one intravitreal injection of 2.5 mg Bevacizumab 3-5 days before performing pars plana vitrectomy
Study: NCT01187095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: 3 consecutive days of writing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active ctrl
Description: Control
Study: NCT04165863

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total knee replacement surgery
Description: total knee replacement surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total knee replacement surgery
Description: total knee replacement surgery
Study: NCT02980757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide 120 mg MR Tablets Formula A